Canntab Therapeutics has been granted its first patent in Australia for its proprietary cannabidiol hard-pill formulations and received a $400k purchase order from Australian partner Cann Global.
The company now has patent protection in the US, Canada and Australia with a further 11 applications pending internationally.
The products ordered by Cann Global will be distributed throughout Australia to doctors, pharmacies and hospitals subject to Canntab’s export licence being approved by Health Canada.
Canntab will also participate in the Applied Cannabis Research Observational Study through the products it supplies to Cann Global.
Canntab CEO Larry Latowsky said: “These are two major milestones that confirm our proprietary formulations are unique and different from other product offerings in the global marketplace.
“With recent developments in the Australian market and the increasing acceptance of medical cannabis we are quite confident that our partnership with and supply to Cann Global will contribute to our planned growth.”
